Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 91Myelodysplastic Syndromes 26Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 8Leukemia 6Hematologic Neoplasms 5Recurrence 4Leukemia, Biphenotypic, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Hematologic Diseases 3Anemia, Refractory, with Excess of Blasts 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Neutrophilic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Immunoblastic Lymphadenopathy 2Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma, Myeloid 1Pathologic Complete Response 1Neurofibromatosis 1 1Neoplasm Metastasis 1

Interventions

fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Specimen Handling 1Methotrexate 1Lenalidomide 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GATA2 Deficiency × Azacitidine × 90 days × Clear all
NCT01522976 2026-04-30

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡